229 results on '"Liverton, Nigel"'
Search Results
2. Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs
3. Indazole to 2‐Cyanoindole Scaffold Progression for Mycobacterial Lipoamide Dehydrogenase Inhibitors Achieves Extended Target Residence Time and Improved Antibacterial Activity.
4. Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055
5. Evolution of HCV NS3/4a Protease Inhibitors
6. Addition to “Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation”
7. Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation
8. Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
9. Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
10. Structure–Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors─Part II
11. Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates
12. Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
13. Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors
14. Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs
15. A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors
16. Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10)
17. A chemical strategy toward novel brain-penetrant EZH2 inhibitors
18. HCV NS3/4a Protease Inhibitors: Simeprevir (TMC‐435350), Vaniprevir (MK‐7009) and MK‐5172
19. Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions
20. MK-5172, a Novel Macrocyclic Inhibitor of NS3/4a Protease Demonstrates Efficacy Against Viral Resistance in the Chimpanzee Model of Chronic Hepatitis C Virus Infection: 17
21. A total synthesis of zoapatanol
22. A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.
23. Molecular basis for p38 protein kinase inhibitor specificity
24. Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux
25. General photoisomerization approach to trans-benzobicyclo(5.1.0)octenes: synthetic and mechanistic studies
26. Total synthesis of the latrunculins
27. Front Cover: Development of a New Structural Class of Broadly Acting HCV Non‐Nucleoside Inhibitors Leading to the Discovery of MK‐8876 (ChemMedChem 17/2017)
28. Development of a New Structural Class of Broadly Acting HCV Non‐Nucleoside Inhibitors Leading to the Discovery of MK‐8876
29. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2–P4 linkers
30. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease
31. Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N ‐methyl‐D‐aspartate receptor antagonist
32. P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325
33. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel
34. Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
35. MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
36. Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists
37. Phosphorous acid analogs of novel P2–P4 macrocycles as inhibitors of HCV–NS3 protease
38. Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors
39. MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
40. A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease
41. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
42. Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents
43. Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure
44. ChemInform Abstract: Pyridazine Based Inhibitors of p38 MAPK.
45. Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
46. MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
47. Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2−P4 Macrocycles
48. Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists
49. Bismacrocyclic Inhibitors of Hepatitis C NS3/4a Protease
50. Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.